Comparison
Argireline vs. DSIP
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Research other
CAS no.
616204-22-9
62568-57-4
Molecular weight
888.99 g/mol
848.81 g/mol
Half-life
no data
0.1 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
1
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
1